New Jersey-based drugmaker Insmed gained more than $3 billion in market value Tuesday after reporting clinical trial results for an experimental lung disease drug that impressed analysts. Data from the trial, a Phase 3 study called Aspen, showed that Insmed’s drug can significantly ease the coughing and shortness of breath that people with bronchiectasis frequently experience….
Artificial intelligence (AI) has sparked a revolution in the pharmaceutical industry, reshaping the way we approach complex biological challenges. “From personalized medicine to unraveling the mysteries of our DNA, we’re witnessing a new era—one where algorithms collaborate with scientists, pushing the boundaries of what’s possible,” says Seema Sayani, Ph.D., Senior Director of Life Sciences with…
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a line! Today, a brief rundown of news from Boehringer Ingelheim, as well as notes on GSK, Bristol Myers Squibb, Exscientia and Regeneron that you may…
Dive Brief: Shares in Cytokinetics sank by about one-fifth Thursday on news of a funding deal the biotechnology company struck with Royalty Pharma, in which it traded away a stake in future sales of its experimental heart drug for upfront cash. The agreement will give Cytokinetics $250 million at closing and as much as $575…
Dive Brief: German drugmaker Merck KGaA agreed to buy Mirus Bio for $600 million to build expertise in a critical part of viral vector-based gene therapy production. Merck KGaA is making the purchase through its U.S. and Canadian life sciences unit, MilliporeSigma. The addition will bolster the company’s Life Science division, which offers contract development…
Orna Therapeutics, a young biotechnology company focused on a flashy area of genetic research, is expanding through the acquisition of another well-funded startup. As its name suggests, the startup, ReNAgade Therapeutics, was built around technology designed to more effectively deliver RNA-based medicines to specific parts of the body. ReNAgade launched a year ago, with $300…
Eli Lilly plans to spend another $5.3 billion building production capacity for its popular obesity and diabetes drugs, responding to immense demand for the medicines with what it claims is now the largest investment of its kind in U.S. history. The commitment announced by Lilly Friday adds to $3.7 billion the drugmaker already planned to…
A top Food and Drug Administration official on Friday again advocated for the speedy approval of gene therapies for rare diseases. But he didn’t drop any clues on where the agency stands on a coming decision to possibly broaden use of one of them, a Duchenne muscular dystrophy treatment the regulator cleared last year. At…
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a line! Today, we’re interrupting our usual rundown of industry news to highlight notable clinical trial updates ahead of next week’s American Society of Clinical Oncology’s…
An older form of hormone therapy taken to ease the symptoms of menopause could increase the risk of ovarian cancer, according to results released Thursday from two studies involving tens of thousands of women. Another hormonal regimen didn’t seem to carry this same risk, researchers found. The results should help settle debate over the relative…
